CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

NCT05744687 · Phase 2 · Recruiting

PHASEPhase 2

STATUSRecruiting

ENROLLMENT374

EST. COMPLETION2026-05-31

Conditions

Locally Advanced or Metastatic Breast Cancer

Interventions

SPH4336 Tablets 400mgSPH4336 Tablets Placebo

Study details

SPONSORShanghai Pharmaceuticals Holding Co., Ltd

START DATE2023-04-24

Related company profiles

Shanghai Pharmaceuticals Holding

2607.HK

Primary source

ClinicalTrials.gov record NCT05744687 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT05744687
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record